Illumina reports a 24% increase in sales to $1.42 billion from the previous year of $1.15 billion.
“The fourth quarter capped off a spectacular year for Illumina with robust performance across all products and geographies,” stated Jay Flatley, CEO. “We made significant progress on key R&D programs which allowed us to introduce new products in early 2014 that will once again redefine the trajectory of sequencing. We plan to leverage this momentum in 2014 to more broadly enable the adoption of genomics.”
For more details, click here: Illumina Reports Q4 and Full Year 2013 Results